Denna sida på svenska This page in English


Immunovia AB

Immunovia AB was founded in 2007. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis. The company now performs clinical validation studies for commercialization of IMMray™ PanCan-d, which has the potential to become the first blood-based test for early diagnosis of cancer of the pancreas. In December 2015, the largest diagnostic retrospective study with 1400 blood samples, showed that IMMray™ PanCan-d is able to detect 98% of pancreatic cancers. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation.

Immunovia's home page

Cantagaria AB

Specialises in antibody-based cancer treatment. Cantargia has designed antibodies, with the initial focus on treatment of non-small cell lung cancer and pancreatic cancer. The platform will be further explored by generation of new antibodies designed for treatment of autoimmune/inflammatory diseases.

Cantargia's home page

Akuru Pharma

Kidney cancer affects more than 300 000 people per year globally, and approximately half of the patients succumb to the disease. It is therefore of great importance to develop novel diagnostic and therapeutic modalities. Akuru is focusing on exploiting transporter proteins for this purpose. Transporter proteins often display a high degree of tissue specificity and can be used as specific biomarkers, but also as tools for delivery of toxic or radioactive compounds to tumor cells. Based on the identification of a transporter protein, uniquely expressed in the most common type of kidney cancer, ccRCC.  

Akuru is participating in a phase IIb clinical study for diagnosis of the disease. Akuru is also developing liquid biopsy assays for early detection and monitoring of disease progression. 

Akuru Pharma's home page